Literature DB >> 6175561

Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis.

A Uchida, E M Maida, R Lenzhofer, M Micksche.   

Abstract

Peripheral blood lymphocytes from patients with multiple sclerosis (MS) were studied for natural killer (NK) cell activity and reactivity to interferon. NK activity determined at the same time in a 4-hr chromium-51 release assay using K562 target cells was significantly lower in MS patients than in controls. In-vitro treatment of MS lymphocytes with interferon resulted in only a slight increase in NK activity, while NK activity of normal individuals was markedly augmented by interferon. Leukopheresis of MS patients gave a rapid decrease in cytotoxic activity, which returned to pretreatment levels by 24 hrs. These results are consistent with the hypothesis of an immune deficit in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175561     DOI: 10.1016/S0171-2985(82)80003-X

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  10 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 2.  The role of natural killer cells in curbing neuroinflammation.

Authors:  Benjamin M Segal
Journal:  J Neuroimmunol       Date:  2007-09-29       Impact factor: 3.478

3.  CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation.

Authors:  Laura Hertwig; Isabell Hamann; Silvina Romero-Suarez; Jason M Millward; Rebekka Pietrek; Coralie Chanvillard; Hanna Stuis; Karolin Pollok; Richard M Ransohoff; Astrid E Cardona; Carmen Infante-Duarte
Journal:  Eur J Immunol       Date:  2016-07-14       Impact factor: 5.532

Review 4.  Regulatory NK-cell functions in inflammation and autoimmunity.

Authors:  Anna Lünemann; Jan D Lünemann; Christian Münz
Journal:  Mol Med       Date:  2009-05-11       Impact factor: 6.354

5.  Past infectious events and disease evolution in multiple sclerosis.

Authors:  G Lamoureux; Y Lapierre; G Ducharme
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

6.  Normal T cell subsets and lymphocyte activity in multiple sclerosis.

Authors:  M M Albala; D Davignon; L D Fast; D D Clark
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

7.  Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.

Authors:  E Braakman; A van Tunen; A Meager; C J Lucas
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

8.  Rps27a might act as a controller of microglia activation in triggering neurodegenerative diseases.

Authors:  Nasibeh Khayer; Mehdi Mirzaie; Sayed-Amir Marashi; Maryam Jalessi
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

9.  Autologous enhancement by interferon of natural killer activity of human peripheral blood lymphocytes.

Authors:  S B Cheknev; Y G Ashmanova; A D Pritsker; O L Latysheva; F I Yershov; A J Kulberg
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

10.  Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.

Authors:  Jan Dörr; Carmen Infante-Duarte; Svenja C Schwichtenberg; Anne Wisgalla; Maria Schroeder-Castagno; Cesar Alvarez-González; Stephan Schlickeiser; Nadja Siebert; Judith Bellmann-Strobl; Klaus-Dieter Wernecke; Friedemann Paul
Journal:  Neurotherapeutics       Date:  2021-07-09       Impact factor: 7.620

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.